DSS, INC. (DSS) - Form 10-Q Summary
Business Context and Reporting Period
This summary covers the quarterly period ended June 30, 2026. DSS, Inc. operates four distinct business lines: Product Packaging (Premier Packaging), Biotechnology (Impact BioMedical), Commercial Lending (American Pacific Financial), and Securities and Investment Management (including a REIT). The company is a non-accelerated filer and a smaller reporting company.
Key Financial Metrics
| Metric | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|
| Total Revenue | $7,934,000 | $10,237,000 |
| Net Loss | $(11,262,000) | $(7,902,000) |
| Net Loss Attributable to Common Stockholders | $(10,389,000) | $(6,929,000) |
| Operating Loss | $(9,274,000) | $(7,151,000) |
| Cash and Cash Equivalents (End of Period) | $4,068,000 | $9,484,000 |
| Working Capital | $(39,874,000) | $(33,151,000) |
| Total Debt (Current + Long-Term) | $35,593,000 (Principal) | $44,030,000 (Principal) |
| Accrued Interest on Long-Term Debt | $8,332,000 | $7,162,000 |
Material Changes vs. Prior Period
- Revenue Decline: Total revenue decreased 22% year-over-year. Product Packaging revenue fell 10% due to customer order shortfalls and delayed onboarding. Securities revenue dropped 75% primarily due to the sale of real estate facilities in 2025 and reduced commission income.
- Increased Losses: Net loss increased 43% to $11.3 million. This was driven by the revenue decline and a significant one-time stock-based compensation expense of $1.44 million at the Impact BioMedical subsidiary.
- Investment Volatility: The company recorded a $1.53 million loss on investments (unrealized and realized) compared to a $627,000 gain in the prior year. A $367,000 loss was recognized on an equity method investment.
- Debt Structure: While total principal debt decreased, the company issued significant new convertible notes to related parties ($2.45 million and $1.0 million) in 2026. A major $40.3 million loan (LifeCare Agreement) remains in default with demand for payment made in late 2023.
Outlook, Risks, and Contingencies
- Going Concern: Management has raised substantial doubt about the company's ability to continue as a going concern. The company has negative working capital of approximately $39.9 million and relies on asset sales, additional financing, and expense reductions to meet obligations.
- Related Party Transactions: Significant financing and investment activities involve related parties, including Alset International Limited and True Partners Capital Holding Limited. A convertible bond from True Partners was converted into equity in April 2026.
- Internal Controls: The company disclosed material weaknesses in internal controls over financial reporting that remained unremediated as of June 30, 2026.
- Pending M&A: A merger agreement with Dr. Ashleys Limited is pending regulatory approval, with closing expected in Q4 2026.
Investor Verification Checklist
- Liquidity Runway: Verify the sufficiency of the $4.1 million cash balance against the $39.9 million negative working capital and the status of the defaulted $40.3 million LifeCare debt.
- Related Party Valuations: Scrutinize the fair value assumptions used for convertible notes and warrants issued to related parties (Alset, True Partners), which resulted in significant non-cash accounting entries.
- Revenue Quality: Assess the sustainability of the Product Packaging segment given the reported customer order shortfalls and the 24% sequential revenue drop.
- Internal Controls: Review the specific remediation plan for the material weaknesses in disclosure controls and financial reporting.
- Investment Portfolio: Confirm the valuation and liquidity of the $2.8 million in marketable securities, which show significant unrealized losses.